Epco, Zanu, Ritux for R/R FL or MZL
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Zanubrutinib
Related studies linked through entity extraction aliases.
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T
- Status
- RECRUITING
- Phase
- PHASE2
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Safety and Efficacy of Zanubrutinib in Refractory/Relapsed Autoimmune Hemolytic Anemia
- Status
- RECRUITING
- Phase
- PHASE2